The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis

Kidney International

Volumn 82, Issue 7, 2012, Pages 759-770

  Zhou, Li Li ^a   Cao, Wei ^a   Xie, Chao ^a   Tian, Jianwei ^a   Zhou, Zhanmei ^a   Zhou, Qiugen ^a   Zhu, Ping ^b   Li, Aiqing ^a   Liu, Youhua ^a   Miyata, Toshio ^c   Hou, Fan Fan ^a   Nie, Jing ^a  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

AOPPs; apoptosis; podocyte; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED OXIDATION PROTEIN PRODUCT; CASPASE; IMMUNOGLOBULIN G ANTIBODY; PROTEIN BAX; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA; SUPEROXIDE;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROTECTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84866419120     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.184     Document Type: Article

References (50)

1. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl 2005; 68: S7-S10.
2. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634.
3. Toyoda M, Najafian B, Kim Y et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007; 56: 2155-2160.
4. White KE, Bilous RW. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant 2004; 19: 1437-1440.
5. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
6. Steffes MW, Schmidt D, McCrery R et al. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 2001; 59: 2104-2113.
7. Lemley KV, Lafayette RA, Safai M et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61: 1475-1485.
8. Lemley KV, Lafayette RA, Derby G et al. Prediction of early progression in recently diagnosed IgA nephropathy. Nephrol Dial Transplant 2008; 23: 213-222.
9. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313.
10. Witko-Sarsat V, Friedlander M, Nguyen Khoa T et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532.
11. Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002; 51: 597-604.
12. Martin-Gallan P, Carrascosa A, Gussinye M et al. Biomarkers of diabetesassociated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003; 34: 1563-1574.
13. Atabek ME, Keskin M, Yazici C et al. Protein oxidation in obesity and insulin resistance. Eur J Pediatr 2006; 165: 753-756.
14. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T et al. Early prediction of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers. Kidney Int 2004; 66: 1606-1612.
15. Li HY, Hou FF, Zhang X et al. Advanced oxidation protein products accelerate renal fibrosis in a remnant kidney model. J Am Soc Nephrol 2007; 18: 528-538.
16. Shi XY, Hou FF, Niu HX et al. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 2008; 149: 1829-1839.
17. Tanji N, Markowitz GS, Fu C et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11: 1656-1666.
18. Takemura T, Yoshioka K, Aya N et al. Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 1993; 43: 918-927.
19. Mayrhofer C, Krieger S, Huttary N et al. Alterations in fatty acid utilization and an impaired antioxidant defense mechanism are early events in podocyte injury: a proteomic analysis. Am J Pathol 2009; 174: 1191-1202.
20. Marsche G, Semlitsch M, Hammer A et al. Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway. FASEB J 2007; 21: 1145-1152.
21. Marsche G, Frank S, Hrzenjak A et al. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res 2009; 104: 750-757.
22. Guo ZJ, Niu HX, Hou FF et al. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 2008; 10: 1699-1712.
23. Zhou LL, Hou FF, Wang GB et al. Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms. Kidney Int 2009; 76: 1148-1160.
24. Naka Y, Bucciarelli LG, Wendt T et al. RAGE axis: animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 2004; 24: 1342-1349.
25. Ritthaler U, Deng Y, Zhang Y et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 1995; 146: 688-694.
26. Liu Y. Advanced oxidation protein products: a causative link between oxidative stress and podocyte depletion. Kidney Int 2009; 76: 1125-1127.
27. Yan SF, Ramasamy R, Naka Y et al. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93: 1159-1169.
28. Chang JS, Wendt T, Qu W et al. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res 2008; 102: 905-913.
29. Bucciarelli LG, Ananthakrishnan R, Hwang YC et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 2008; 57: 1941-1951.
30. Yan SF, Yan SD, Ramasamy R et al. Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med 2009; 41: 408-422.
31. Nishi S, Alchi B, Imai N et al. New advances in renal amyloidosis. Clin Exp Nephrol 2008; 12: 93-101.
32. Pala L, Cresci B, Manuelli C et al. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: biological effects and advanced glycosilation end products modulation. Microvasc Res 2005; 70: 179-188.
33. Gu L, Hagiwara S, Fan Q et al. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-productinduced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006; 21: 299-313.
34. Guo J, Ananthakrishnan R, Qu W et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol 2008; 19: 961-972.
35. Flyvbjerg A, Denner L, Schrijvers BF et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004; 53: 166-172.
36. Iwao Y, Nakajou K, Nagai R et al. CD36 is one of important receptors promoting renal tubular injury by advanced oxidation protein products. Am J Physiol Renal Physiol 2008; 295: F1871-F1880.
37. D'Agati V, Yan SF, Ramasamy R et al. RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells. Trends Endocrinol Metab 2010; 21: 50-56.
38. Hofmann MA, Drury S, Hudson BI et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002; 3: 123-135.
39. Schmidt AM, Yan SD, Yan SF et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-955.
40. Hou FF, Miyata T, Boyce J et al. Beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. Kidney Int 2001; 59: 990-1002.
41. Liu SX, Hou FF, Guo ZJ et al. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 1156-1162.
42. Nagai R, Hayashi CM, Xia L et al. Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehydemodified proteins. J Biol Chem 2002; 277: 48905-48912.
43. Kaji Y, Usui T, Oshika T et al. Advanced glycation end products in diabetic corneas. Invest Ophthalmol Vis Sci 2000; 41: 362-368.
44. Sady C, Jiang CL, Chellan P et al. Maillard reactions by alphaoxoaldehydes: detection of glyoxal-modified proteins. Biochim Biophys Acta 2000; 1481: 255-264.
45. Zhu P, Tang L, Zhao SC et al. Preparation of monoclonal antibodies against different epitopes on extracellular domain of human receptor for advanced glycation end product. Di Yi Jun Yi Da Xue Xue Bao 2004; 24: 129-132.
46. Liu B, Hou X, Zhou Q et al. Detection of advanced oxidation protein products in patients with chronic kidney disease by a novel monoclonal antibody. Free Radic Res 2011; 45: 662-671.
47. Guo X, Wang L, Chen B et al. ERM protein moesin is phosphorylated by advanced glycation end products and modulates endothelial permeability. Am J Physiol Heart Circ Physiol 2009; 297: H238-H246.
48. Ge J, Jia Q, Liang C et al. Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells. Arterioscler Thromb Vasc Biol 2005; 25: 2157-2163.
49. Mundel P, Reiser J, Zuniga Mejia Borja A et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-258.
50. Zhu F, Li T, Qiu F et al. Preventive effect of Notch signaling inhibition by a gamma-secretase inhibitor on peritoneal dialysis fluid-induced peritoneal fibrosis in rats. Am J Pathol 2010; 176: 650-659.